Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
繁
中
繁
中
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
Investor Relations
>
Investor Relations
>
Announcements and Circulars
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Announcements and Circulars
Search
Dec 31, 2019
Change of company secretary and authorised representative
Read More
Dec 05, 2019
Supplemental announcement discloseable transaction in relation to tenancy agreement
Read More
Dec 05, 2019
Monthly Return
Read More
Dec 03, 2019
Discloseable transaction in relation to tenancy agreement
Read More
Nov 14, 2019
Grant of share options
Read More
Nov 12, 2019
Business update on first phase III monotherapy trial of dorzagliatin
Read More
Nov 07, 2019
Monthly Return
Read More
Oct 05, 2019
Monthly Return
Read More
Sep 04, 2019
Monthly Return
Read More
Sep 03, 2019
Grant of share options
Read More
Aug 30, 2019
Business Update Completion Of Patient Enrollment For Phase III Combination Trial Of Dorzagliatin
Read More
Aug 23, 2019
Supplemental announcement in relation to the interim results announcement 2019
Read More
<<
<
7
8
9
10
11
12
13
14
15
16
17
>
>>
上一页
下一页
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Subscribe Email
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号
Search